2019 Press Releases

Keyword Search
 
May 15, 2019
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs
Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileucel following failure of checkpoint inhibitors had objective response rate of 38 percent First patient dosed in IOV-COM-202; the first time that Iovance TIL therapy has been administered in a PD-1/PD-L1 naive patient population SAN CARLOS, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)... More »
May 7, 2019
Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
- First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for late 2020 - - New interim data from melanoma Cohort 2 and cervical cancer studies to be presented in June at the 2019 American Society of Clinical Oncology (ASCO) meeting - - Company to host conference call at 4:30 p.m. EDT today - SAN CARLOS, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developi... More »
May 2, 2019
Iovance Biotherapeutics to Participate in Upcoming Conferences in May
SAN CARLOS, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to participate in the following conferences in May: NYAS Frontiers in Cancer Immunotherapy in New York, May 14-15, 2019             Panel Presentation: Will CAR-T Cell Therapies, Bispecific Antibodies, or TILs Be More ... More »
May 1, 2019
Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019
SAN CARLOS, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT. To participate in the conf... More »
April 3, 2019
Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting
Presentations to provide updated data from Cohort 2 of the innovaTIL-01 (C-144-01) study in advanced melanoma and the innovaTIL-04 (C-145-04) study in cervical cancer SAN CARLOS, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that new interim data from Cohort 2 of the innovaTIL-01 (C-144-01) study and data fr... More »
April 3, 2019
Iovance Biotherapeutics Announces Clinical Programs Update
- Design of cervical cancer study amended in anticipation for regulatory interactions -             -  Global IOV-COM-202 study to add new combination arm for patients with non-small cell lung cancer; IOV-LUN-201 study to close - SAN CARLOS, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced an update to it... More »
April 2, 2019
Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma
- Patient dosing commenced in pivotal metastatic melanoma cohort - - Submission for regulatory approval of lifileucel is on target for late 2020 - SAN CARLOS, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that first patient has been dosed in Cohort 4, the pivotal cohort of the innovaTIL-01 (C-144-01) s... More »
April 1, 2019
Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel
- Data from cohort 2 of the innovaTIL-01 study support polyclonal approach necessary to treat metastatic melanoma - SAN CARLOS, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced data from an investigation of the persistence and diversity of circulating T cells from metastatic melanoma patients from the inno... More »
March 29, 2019
Iovance Biotherapeutics Announces April Scientific and Investor Presentations
SAN CARLOS, Calif., March 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present at the following conferences in April: American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29-April 3 Title: Persistence of cryopreserved tumor-infiltrating lymphocyte product lifile... More »
March 6, 2019
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March
SAN CARLOS, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will participate and present at the following investors conferences in March: Cowen and Company 39th Annual Health Care Conference in Boston, March 11-13, 2019 Location: Boston Marriott Copley Place Date/Time: Wednesday, Ma... More »
February 27, 2019
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
- Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma - - FDA Granted Fast Track Designation for LN-145 for Treatment of Patients with Recurrent, Metastatic or Persistent Cervical Cancer - - Company to Host Conference Call at 4:30 pm EST Today - SAN CARLOS, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymph... More »
February 26, 2019
Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer
SAN CARLOS, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical cancer who have progressed while on or after chemotherapy. LN-145 is the Company's adopti... More »
February 22, 2019
Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019
SAN CARLOS, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and year-end 2018 financial results on Wednesday, February 27, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST. To participate... More »
February 1, 2019
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences
SAN CARLOS, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will participate and present at the following upcoming conferences: 5th Annual Immuno-Oncology 360° conference in New York, February 6-8, 2019 Presenter: Maria Fardis, Ph.D., President and Chief Executive Officer Session: Next Generati... More »